糖蛋白非转移性黑色素瘤蛋白B作为头颈癌治疗后转移的潜在影像标志物
该回顾性研究分析了40例接受放化疗后行挽救性颈清扫患者的淋巴结标本,采用免疫组化H评分评估EGFR、GPNMB和VEGF的表达。结果显示GPNMB在存活肿瘤淋巴结中100%表达,灵敏度100%、特异度75%,其表现与EGFR相当,可能成为未来分子影像的潜在靶点,而VEGF不适用于挽救手术中的影像目的。
要点
- GPNMB在存活肿瘤淋巴结中100%表达,灵敏度100%、特异度75%。
- EGFR在存活肿瘤淋巴结中86%表达,灵敏度86%、特异度81%。
- VEGF在所有淋巴结类型中均表达,不适用于影像目的。
核心结论
- 在残留或复发性HNSCC淋巴结转移中,EGFR和GPNMB均显示肿瘤特异性免疫组化表达,可能有助于未来挽救性颈清扫的分子影像。
- 免疫组化检测的VEGF表达表明该靶点在挽救手术中不适用于影像目的。
- GPNMB可能是新的潜在影像靶点,在免疫组化中显示出与EGFR相当的结果。
研究设计与样本
- 回顾性研究,比较初始治疗后配对淋巴结中的受体表达。
- 三级转诊医院,选取40例接受放化疗后行挽救性颈清扫患者的标本。
- 采用免疫组化H评分分析含存活肿瘤、初始治疗后反应性改变和正常的淋巴结,并计算灵敏度、特异度及阳性/阴性预测值。
主要发现
- EGFR在86%的存活肿瘤淋巴结中表达,GPNMB在100%的存活肿瘤淋巴结中表达。
- VEGF在所有淋巴结类型中均表达。
- EGFR的灵敏度为86%,特异度为81%;GPNMB的灵敏度为100%,特异度为75%。
- EGFR的PPV为61.8%,NPV为98.2%;GPNMB的PPV为56.4%,NPV为100%。
关键数值与推荐
- EGFR在存活肿瘤淋巴结中表达率86%,灵敏度86%,特异度81%,PPV 61.8%,NPV 98.2%。
- GPNMB在存活肿瘤淋巴结中表达率100%,灵敏度100%,特异度75%,PPV 56.4%,NPV 100%。
- VEGF在所有淋巴结类型中均表达。
临床怎么用
- GPNMB和EGFR的免疫组化表达特征支持其作为未来分子影像靶点的潜力,用于挽救性颈清扫术前评估。
- VEGF因在所有淋巴结类型中均表达,不适合作为挽救手术中的影像靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate expression of potential molecular imaging targets epidermal growth factor receptor (EGFR), glycoprotein nonmetastatic melanoma protein B (GPNMB), and vascular endothelial growth factor (VEGF) in lymph nodes (LNs) with or without head and neck squamous cell carcinoma (HNSCC) metastases after (chemo)radiation. STUDY DESIGN: Retrospective study comparing receptor expression in paired lymph nodes after initial treatment. SETTING: A tertiary referral hospital. SUBJECTS AND METHODS: Salvage neck dissection specimens of 40 patients treated with (chemo)radiation were selected. LNs that contained viable tumor, reactive changes after initial treatment, and normal LNs were analyzed using immunohistochemically determined H-scores and by calculating sensitivity and specificity rates and positive/negative predictive values (PPVs/NPVs). RESULTS: EGFR expression was found in 86% and GPNMB expression in 100% of the LNs with viable tumor. VEGF expression was present in all lymph node types. For EGFR, the sensitivity rate was 86%, and specificity rate was 81%. For GPNMB, these were 100% and 75%, respectively. PPV of EGFR was 61.8% and NPV was 98.2%. These were 56.4% and 100% for GPNMB, respectively. CONCLUSION: In residual or recurrent HNSCC lymph node metastases, both EGFR and GPNMB show tumor-specific expression in immunohistochemistry, which may prove useful in future molecular imaging in salvage neck dissections. Immunohistochemically detected VEGF expression indicates that this target is not feasible for imaging purposes in salvage surgery. Therefore, GPNMB could be a new potential imaging target showing comparable results to EGFR in immunohistochemistry.
引用
- van Schaik JE, Hanemaaijer SH, Halmos GB, et al. Glycoprotein Nonmetastatic Melanoma Protein B as Potential Imaging Marker in Posttherapeutic Metastatic Head and Neck Cancer. Otolaryngol Head Neck Surg. 2020. PMID: 32600105. doi:10.1177/0194599820932869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。